AstraZeneca Shares Plunge 8.9% After Ionis Trial Failure as Alnylam Soars
AZN•AstraZeneca shares plunged 8.9% in London trading after a co-developed late-stage trial with partner Ionis Pharmaceuticals failed to meet its primary endpoints, sending Ionis stock sharply lower. Rival Alnylam saw its shares surge on positive clinical news, highlighting a stark divergence in biotech market sentiment.
1. Trial Failure and Pipeline Impact
AstraZeneca and Ionis Pharmaceuticals’ co-developed late-stage trial failed to achieve its primary efficacy endpoints, leading to immediate discontinuation of the study and prompting a review of their collaborative R&D strategy.
2. Market Reaction and Stock Movements
Following the trial setback, AstraZeneca shares fell 8.9% in London and Ionis stock sank sharply, while competitor Alnylam’s shares rallied strongly on its own positive clinical data, underscoring divergent investor preferences within the biotech sector.
